COVID-19 in Children: New Study Examines Age-Related Protection Mechanisms

Strategic Insights -

A new study on Coronavirus Disease 2019 (COVID-19) has shed light on the mechanisms underlying the milder symptoms and lower mortality rates observed in children compared to adults. The research, conducted before the introduction of mass COVID-19 vaccination, examined the association between serum levels of angiotensin-converting enzyme 2 (ACE2) and IgG antibody titers against Measles, Mumps, and Rubella (MMR) vaccines and susceptibility to SARS-CoV-2 infection in the pediatric population. The study found no significant association between serum ACE2 levels or MMR antibody titers and protection against COVID-19 in children.

Key Takeaways:

  • The study consisted of 83 patients, including 39 cases with COVID-19 infection and 44 controls with non-infectious, non-immunodeficient conditions and no documented history of COVID-19.
  • The median serum ACE2 levels were 3.6 in COVID-19 cases and 3.8 ng/mL in control cases, with no significant difference (P=0.440).
  • Antibody levels against Mumps, Measles, and Rubella did not differ significantly between the groups, although Rubella seropositivity was more frequent in COVID-19 cases than in controls (P=0.039).
  • The study concluded that the higher prevalence of Rubella seropositivity among infected cases may suggest possible cross-reactivity, but causal relationships could not be established.

Statistics:

  • 83 patients were enrolled in the study, including 39 cases with COVID-19 infection and 44 controls.
  • The median serum ACE2 levels were 3.6 in COVID-19 cases and 3.8 ng/mL in control cases.
  • Antibody levels against Mumps, Measles, and Rubella were assessed using ELISA.
  • The study showed no significant association between serum ACE2 levels or MMR antibody titers and protection against COVID-19 in children (P-values: 0.440, 0.788, 0.281, and 0.083).

Sources:

  • Iranian Journal of Immunology, 2025;22(3):7.
  • Serum ACE2 and Anti-MMR Antibody Profiles in Pediatric Patients with and without SARS-CoV-2 Infection, Iranian Journal of Immunology, 2025;22(3):7.
  • Shiraz Inst Cancer Res, Shiraz Univ Med Sci, Iranian Soc Immunol & Allergy, PO Box 71345-3119, Shiraz, 00000, Iran
  • Iranian Journal of Immunology can be contacted at: Shiraz Inst Cancer Res, Shiraz Univ Med Sci, Iranian Soc Immunol & Allergy, PO Box 71345-3119, Shiraz, 00000, Iran.